Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT005 gene therapy in geographic atrophy secondary to AMD
NCT04437368Phase 2Terminated
- Sponsor
- Gyroscope Therapeutics
- Start
- Apr 2019
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 8
01
Overview
A Phase 2 trial of GT005, sponsored by Gyroscope Therapeutics. Started Apr 2019; status: terminated.
02
Drugs
GT005
Beyond the preview
Go deeper on NCT04437368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04437368.